Prothena Corp. (PRTA) Looks Good: Stock Moves Up 5.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Dec 22, 7:51AM CST
Prothena Corporation plc (PRTA) was a big mover last session, as its shares rose almost 6% on the day.
BIIB: 340.89 (+5.13), PRTA: 20.14 (+1.41)
After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 4:37PM CST
NOW: 69.69 (+0.12), WIT: 11.81 (-0.05), AG: 4.77 (+0.21), DGII: 9.15 (+0.15), BBEP: 7.06 (-0.23), NGD: 4.18 (+0.16), IAG: 2.41 (+0.06), VIIX: 38.17 (-0.37), PRTA: 20.14 (+1.41), CDE: 5.11 (+0.31)
Prothena mAb Fast Track'd for AL Amyloidosis
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 4:05PM CST
PRTA: 20.14 (+1.41)
Prothena Receives FDA Fast Track Designation for NEOD001, a Monoclonal Antibody for the Treatment of Patients With AL Amyloidosis
GlobeNewswire - Mon Dec 15, 3:10PM CST
-- First Investigational Immunotherapy for AL Amyloidosis to Receive FDA Fast Track Designation
PRTA: 20.14 (+1.41)
Commit To Purchase Prothena Corp At $17.50, Earn 33.1% Annualized Using Options
at The Street - Fri Dec 12, 10:45AM CST
Investors considering a purchase of Prothena Corp plc shares, but tentative about paying the going market price of $17.97/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put...
PRTA: 20.14 (+1.41)
First patient enrolled in Acorda Phase 3 PD trial
Seeking Alpha - at Seeking Alpha - Wed Dec 10, 7:06AM CST
IPXL: 31.32 (+0.26), ADMS: 16.10 (+1.45), TEVA: 57.09 (+0.33), ACOR: 39.14 (+0.74), PRTA: 20.14 (+1.41), NDRM: 5.90 (-0.19)
Prothena to Present at the Oppenheimer 25th Annual Healthcare Conference in New York
GlobeNewswire - Mon Dec 08, 4:11PM CST
Prothena Corporation plc (Nasdaq
PRTA: 20.14 (+1.41)
Prothena Corporation (PRTA) Falls: Stock Goes Down 5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Dec 04, 7:37AM CST
Shares of Prothena Corporation (PRTA) fell over 5% on the day. This continues the most recent downtrend for PRTA, as the stock is down over 9% since Nov 28. Although this slump was obviously disappointing the company has seen positive revisions and its current year loss consensus has narrowed over the past few weeks.
BIIB: 340.89 (+5.13), ANIP: 55.24 (+1.79), PRTA: 20.14 (+1.41), AFFX: 9.80 (+0.05)
Prothena Initiates NEOD001 Global Phase 3 Registrational Trial Based on Positive Results in Ongoing Phase 1/2 Study of NEOD001 in Patients With AL Amyloidosis
Thomson Reuters ONE - Tue Dec 02, 3:05PM CST
- New and Updated Results Show 50% Response Rate in 14 Cardiac-Evaluable Patients
PRTA: 20.14 (+1.41)
Why You Shouldn't Bet Against Prothena Corporation (PRTA) Stock - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Dec 01, 7:43AM CST
Prothena Corporation might be an intriguing choice for investors as it is seeing solid earnings estimate revision activity and is in great company from a Zacks Industry Rank perspective
PRTA: 20.14 (+1.41)
Prothena's Management Presents at 2014 Credit Suisse Healthcare Conference (Transcript)
SA Transcripts - at Seeking Alpha - Tue Nov 11, 2:16PM CST
PRTA: 20.14 (+1.41)
Prothena Reports Third Quarter 2014 Financial Results and R&D Progress
GlobeNewswire - Mon Nov 03, 5:29PM CST
-- Net cash used in operating activities was $12.3 million in the third quarter, while quarter-end cash position of $306.2 million provides solid runway for advancement of multiple programs
PRTA: 20.14 (+1.41)
Prothena beats by $0.12, beats on revenue
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 4:06PM CST
PRTA: 20.14 (+1.41)
Genervon ALS drug shows encouraging results
Seeking Alpha - at Seeking Alpha - Mon Oct 20, 7:27AM CDT
BIIB: 340.89 (+5.13), MNOV: 3.04 (unch), CHTP: 6.52 (-0.03), ADMS: 16.10 (+1.45), ACOR: 39.14 (+0.74), BCLI: 3.85 (+0.22), BSX: 13.13 (+0.07), IPXL: 31.32 (+0.26), AVNR: 16.91 (+0.01), ACAD: 30.95 (+0.78), CVTS: (), MRK: 57.46 (+0.25), TEVA: 57.09 (+0.33), PRTA: 20.14 (+1.41), PRAN: 1.74 (-0.02), FOLD: 7.94 (+0.06), CUR: 2.70 (+0.07)
The Next Biotech Buyout Stock
Motley Fool Staff - Motley Fool - Fri Oct 10, 7:15AM CDT
Biotech stocks are notoriously volatile, making them best suited for only the most risk-tolerant investors. But for those willing to take the risk, biotech companies can often make a big splash; particularly when a bigger fish gobbles them up....
JNJ: 104.59 (+0.31), PTLA: 28.35 (+0.21), PFE: 31.42 (-0.03), BMY: 59.15 (-0.01), PRTA: 20.14 (+1.41), PBYI: 189.96 (+0.12)
Why Prothena Corporation (PRTA) Stock Might be a Great Pick - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 25, 7:43AM CDT
Prothena Corporation belongs to the Medical and Biomedical industry, is a decent pick as it witnessed solid earnings estimate revision activity with a favorable Zacks Industry Rank.
PRTA: 20.14 (+1.41)